下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

Biogen Inc. (NASDAQ:BIIB) Shares Bought by Bogart Wealth LLC
生物遗传研究公司(纳斯达克代码:BIIB)被博嘉财富有限责任公司购买的股票

Defense World ·  {{timeTz}}

Bogart Wealth LLC raised its stake in Biogen Inc. (NASDAQ:BIIB – Get Rating) by 1,150.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 200 shares of the biotechnology company's stock after acquiring an additional 184 shares during the quarter. Bogart Wealth LLC's holdings in Biogen were worth $41,000 at the end of the most recent reporting period.

博嘉财富有限责任公司(Bogart Wealth LLC)最近提交给美国证券交易委员会(Securities And Exchange Commission)的Form 13F文件显示,该公司在第二季度将其在Biogen Inc.(纳斯达克代码:BIIB-GET Rating)的持股比例提高了1,150.0%。该公司在本季度增持了184股后,持有200股这家生物技术公司的股票。在最近的报告期结束时,Bogart Wealth LLC在Biogen持有的股份价值41,000美元。

A number of other large investors also recently bought and sold shares of BIIB. PDT Partners LLC acquired a new position in shares of Biogen during the 4th quarter worth approximately $587,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Biogen by 60.5% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 181,499 shares of the biotechnology company's stock worth $43,545,000 after buying an additional 68,400 shares during the period. Cubist Systematic Strategies LLC raised its stake in shares of Biogen by 136.5% during the 4th quarter. Cubist Systematic Strategies LLC now owns 30,668 shares of the biotechnology company's stock worth $7,358,000 after buying an additional 17,700 shares during the period. Cinctive Capital Management LP raised its stake in shares of Biogen by 11.0% during the 4th quarter. Cinctive Capital Management LP now owns 5,034 shares of the biotechnology company's stock worth $1,208,000 after buying an additional 500 shares during the period. Finally, Credit Agricole S A raised its stake in shares of Biogen by 73.4% during the 4th quarter. Credit Agricole S A now owns 607 shares of the biotechnology company's stock worth $146,000 after buying an additional 257 shares during the period. 83.45% of the stock is owned by institutional investors and hedge funds.

其他一些大型投资者最近也买卖了BIIB的股票。PDT Partners LLC在第四季度收购了Biogen公司价值约58.7万美元的新股票头寸。Adage Capital Partners GP L.L.C.在第四季度将其在Biogen的股份增加了60.5%。Adage Capital Partners GP L.L.C.现在拥有181,499股这家生物技术公司的股票,价值43,545,000美元,在此期间又购买了68,400股。Cubist Systems Strategy LLC在第四季度将其在生物遗传公司的股份增加了136.5%。Cubist Systems Strategy LLC现在拥有30,668股这家生物技术公司的股票,价值7,358,000美元,在此期间又购买了17,700股。Cinctive Capital Management LP在第四季度将其在Biogen的股份增加了11.0%。Cinctive Capital Management LP现在拥有这家生物技术公司5,034股股票,价值1208,000美元,在此期间又购买了500股。最后,法国农业信贷银行在第四季度增持了73.4%的生物遗传股份。法国农业信贷银行目前持有这家生物技术公司607股股票,价值14.6万美元,在此期间又购买了257股。83.45%的股票由机构投资者和对冲基金持有。

Get
到达
Biogen
生物遗传研究
alerts:
警报:

Biogen Price Performance

生物遗传价格表现

BIIB stock opened at $267.00 on Monday. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.94 and a quick ratio of 1.68. The firm has a market capitalization of $38.75 billion, a P/E ratio of 19.04, a P/E/G ratio of 1.62 and a beta of 0.16. The business's 50-day moving average is $211.47 and its two-hundred day moving average is $208.53. Biogen Inc. has a 1 year low of $187.16 and a 1 year high of $290.76.

周一,亚投行股票开盘报267.00美元。该公司的债务权益比为0.53,流动比率为1.94,速动比率为1.68。该公司市值387.5亿美元,市盈率19.04倍,市盈率1.62倍,贝塔系数0.16。该业务的50日移动均线切入位在211.47美元,200日移动均线切入位在208.53美元。Biogen Inc.的一年低点为187.16美元,一年高位为290.76美元。

Biogen (NASDAQ:BIIB – Get Rating) last posted its quarterly earnings results on Wednesday, July 20th. The biotechnology company reported $5.25 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.09 by $1.16. The company had revenue of $2.59 billion for the quarter, compared to analyst estimates of $2.48 billion. Biogen had a return on equity of 22.36% and a net margin of 19.36%. Biogen's revenue for the quarter was down 6.7% compared to the same quarter last year. During the same quarter last year, the company earned $5.68 EPS. Analysts anticipate that Biogen Inc. will post 16.44 earnings per share for the current fiscal year.
生物遗传研究公司(纳斯达克代码:BIIB-GET Rating)最近一次公布季度收益是在7月20日星期三。这家生物技术公司公布本季度每股收益(EPS)为5.25美元,超出分析师普遍预期的4.09美元至1.16美元。该公司本季度营收为25.9亿美元,而分析师预期为24.8亿美元。生物遗传研究公司的股本回报率为22.36%,净利润率为19.36%。与去年同期相比,生物遗传研究公司本季度的收入下降了6.7%。去年同期,该公司每股收益为5.68美元。分析师预计,Biogen Inc.将公布本财年每股收益16.44美元。

Wall Street Analyst Weigh In

华尔街分析师也加入进来

Several research firms recently commented on BIIB. Wells Fargo & Company increased their price objective on Biogen from $265.00 to $350.00 and gave the company an "overweight" rating in a research note on Wednesday, September 28th. JPMorgan Chase & Co. increased their price objective on Biogen from $221.00 to $275.00 in a research note on Friday. StockNews.com raised Biogen from a "buy" rating to a "strong-buy" rating in a research note on Wednesday, July 27th. Truist Financial reduced their price objective on Biogen from $270.00 to $265.00 and set a "buy" rating for the company in a research note on Thursday, September 22nd. Finally, Piper Sandler increased their price objective on Biogen from $200.00 to $280.00 and gave the company a "neutral" rating in a research note on Wednesday, September 28th. Ten analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $275.50.

几家研究公司最近对BIIB发表了评论。富国银行将生物遗传的目标价从265.00美元上调至350.00美元,并在9月28日星期三的一份研究报告中给予该公司“增持”评级。摩根大通在周五的一份研究报告中将生物遗传的目标价从221.00美元上调至275.00美元。在7月27日星期三的一份研究报告中,StockNews.com将Biogen的评级从“买入”上调至“强力买入”。9月22日,Truist Financial将Biogen的目标价从270.00美元下调至265.00美元,并在一份研究报告中为该公司设定了“买入”评级。最后,派珀·桑德勒将Biogen的目标价从200.00美元上调至280.00美元,并在9月28日星期三的一份研究报告中给出了该公司“中性”的评级。10位分析师对该股的评级为持有,17位分析师给出了买入评级,一位分析师给出了该公司股票的强烈买入评级。根据MarketBeat的数据,该股目前的共识评级为“适度买入”,共识目标价为275.50美元。

Biogen Profile

生物遗传图谱

(Get Rating)

(获取评级)

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.

生物遗传公司发现、开发、制造和提供治疗神经和神经退行性疾病的疗法。该公司提供Tecfidera、VUMERITY、Avonex、Plegridy、Tysabri和FAMPYRA治疗多发性硬化症(MS);SPINRAZA治疗脊髓性肌肉萎缩;以及FUMADERM治疗斑块型牛皮癣。

See Also

另请参阅

  • Get a free copy of the StockNews.com research report on Biogen (BIIB)
  • Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
  • Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
  • Magna International is Your Auto and EV One-Stop Shop Stock
  • EV Battery Maker Freyr Set For Major Global Expansion
  • MarketBeat: Week in Review 9/26 – 9/30
  • 免费获取StockNews.com关于生物遗传研究报告的副本(BIIB)
  • 阿彻·丹尼尔斯·米德兰:49年增长的红利英雄
  • 全自动拖拉机会让迪尔成为农业领域的特斯拉吗?
  • 麦格纳国际是您的汽车和电动汽车一站式库存
  • 电动汽车电池制造商Freyr将在全球大举扩张
  • MarketBeat:回顾一周9/26-9/30

Want to see what other hedge funds are holding BIIB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biogen Inc. (NASDAQ:BIIB – Get Rating).

想看看其他对冲基金持有哪些BIIB吗?访问HoldingsChannel.com获取生物遗传公司(纳斯达克代码:BIIB-GET Rating)的最新13F备案文件和内幕交易信息。

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.

接受《生物遗传日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Biogen和相关公司的最新新闻和分析师评级的每日简要摘要。

本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。